TY - JOUR
T1 - Celiprolol in systemic hypertension
AU - Frishman, William H.
AU - Flamenbaum, Walter
AU - Schoenberger, James
AU - Schwartz, Gary L.
AU - Vidt, Donald G.
AU - Neri, Gilberto S.
AU - Greenberg, Steven
AU - Lazar, Eliot
AU - Godfrey, John C.
AU - Stevenson, Annette
AU - Lamon, Kim D.
AU - Chang, Yueh
AU - Magner, David J.
N1 - Funding Information:
From the Albert Einstein College of Medicine, Bronx, New York; Pharm Evaluation Services, Englewood Cliffs, New Jersey; Rush-Presbyterian-St. Luke’s Medical Center, Chicago, Illinois; Mayo Clinic and Mayo Foundation, Rochester, Minnesota; the Cleveland Clinic Foundation, Cleveland, Ohio; and Rorer Central Research, Rorer Pharmaceutical Corp., Horsham, Pennsylvania. This study was supported by a grant from Rorer Pharmaceuticals, Horsham, Pennsylvania. Manuscript received September 20, 1988; revised manuscript received December 30,1988, and accepted January 3,1989. Address for reprints: William H. Frishman, MD, 1825 Eastchester Road, Bronx, New York 10461.
PY - 1989/4/1
Y1 - 1989/4/1
N2 - The safety and efficacy of orally administered celiprolol, a new β1-selective adrenergic blocking drug with peripheral β2-agonist properties, were assessed in 91 patients with mild to moderate systemic hypertension (supine diastolic blood pressure [BP] 95 to 114 nun Hg without medication) using a placebo-controlled, double-blind, randomized, titration-to-effect study design. All patients received placebo for 4 weeks and were then randomized to receive placebo (n = 46) or once-daily celiprolol (n = 45), which was titrated every 2 weeks (200, 400, 600 mg/day) over a 6-week period to achieve a reduction in supine diastolic BP to ≤90 mm Hg. Plasma lipids and lipoproteins were also assessed at baseline, during placebo and after randomization to active therapy in a subgroup of patients. Compared with placebo, celiprolol reduced supine and standing BP (reduction of supine BP -0.4 -2.1 mm Hg with placebo, -5.7 -6.4 with celiprolol, p < 0.05; reduction of standing BP -1.7 -1.0 with placebo, -7.2 -4.9 with celiprolol, p < 0.05). Supine heart rate was reduced by 6.8 beats/min with celiprolol compared with 2.0 beats/min with placebo (p < 0.05). No differences were seen when the effects of placebo and celiprolol on plasma lipoproteins were compared. Celiprolol is a safe, effective and well tolerated once-daily antihypertensive drug and has no detrimental effects on plasma lipids.
AB - The safety and efficacy of orally administered celiprolol, a new β1-selective adrenergic blocking drug with peripheral β2-agonist properties, were assessed in 91 patients with mild to moderate systemic hypertension (supine diastolic blood pressure [BP] 95 to 114 nun Hg without medication) using a placebo-controlled, double-blind, randomized, titration-to-effect study design. All patients received placebo for 4 weeks and were then randomized to receive placebo (n = 46) or once-daily celiprolol (n = 45), which was titrated every 2 weeks (200, 400, 600 mg/day) over a 6-week period to achieve a reduction in supine diastolic BP to ≤90 mm Hg. Plasma lipids and lipoproteins were also assessed at baseline, during placebo and after randomization to active therapy in a subgroup of patients. Compared with placebo, celiprolol reduced supine and standing BP (reduction of supine BP -0.4 -2.1 mm Hg with placebo, -5.7 -6.4 with celiprolol, p < 0.05; reduction of standing BP -1.7 -1.0 with placebo, -7.2 -4.9 with celiprolol, p < 0.05). Supine heart rate was reduced by 6.8 beats/min with celiprolol compared with 2.0 beats/min with placebo (p < 0.05). No differences were seen when the effects of placebo and celiprolol on plasma lipoproteins were compared. Celiprolol is a safe, effective and well tolerated once-daily antihypertensive drug and has no detrimental effects on plasma lipids.
UR - http://www.scopus.com/inward/record.url?scp=0024602203&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0024602203&partnerID=8YFLogxK
U2 - 10.1016/0002-9149(89)90053-2
DO - 10.1016/0002-9149(89)90053-2
M3 - Article
C2 - 2522723
AN - SCOPUS:0024602203
SN - 0002-9149
VL - 63
SP - 839
EP - 842
JO - The American journal of cardiology
JF - The American journal of cardiology
IS - 12
ER -